- Home
- ESGL vs SGMT Comparison
ESGL vs SGMT Comparison
Compare ESGL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ESGL | SGMT |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 238.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ESGL | SGMT |
|---|---|---|
| Price | $4.00 | $6.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | 7.4K | ★ 508.9K |
| Earning Date | 12-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,328,277.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $1.73 |
| 52 Week High | $4.32 | $11.41 |
Technical Indicators
Market Signals| Indicator | ESGL | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 39.34 |
| Support Level | $3.80 | $5.95 |
| Resistance Level | $3.95 | $6.58 |
| Average True Range (ATR) | 0.15 | 0.36 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 100.00 | 24.34 |
Price Performance
Historical ComparisonAbout ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.